Redcare Pharmacy

Analysts at Berenberg have raised the price target for Redcare Pharmacy from €94 to €102 and confirm the "Buy" rating. The reason is improved shopping experiences for prescription medicines, which lead to more frequent prescription redemptions and higher basket values. Management has raised its sales forecast for the current year to +16–18%; Rx sales are expected to be €730–760 million. Technically, a sustained breakout above the resistance around €70 did not occur, so investors remain cautious. » Plus sur deraktionaer.de

Deutsche Bank Research has raised the price target for Redcare Pharmacy from €103 to €104 and kept the rating at "Buy." Analyst Jan Koch says the prescription business in Germany remains strong and expects a recovery in sales of non-prescription products in the third quarter. He considers the confirmed operating profit margin to be conservative. » Plus sur finanzen.net

Online pharmacy Redcare Pharmaceuticals has raised its 2026 revenue forecast to +16–18% (previously 15–17%). The expected operating profit margin remains at 2.5–3.0%. The company cites the rapidly growing e-prescription segment in Germany as the main driver; the stock was firmer on Tuesday. » Plus sur finanzen.net